Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 7:19 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 73 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Sicca Syndrome Clear all

Conditions: Sjogren's Syndrome, Keratoconjunctivitis Sicca
Interventions: Levocarnitine, Placebo; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Dry Eye
Interventions: ECF843, ECF843 vehicle; Drug · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 718 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 52
States / cities: Chandler, Arizona • Mesa, Arizona • Phoenix, Arizona + 46 more

Conditions: Keratoconjunctivitis Sicca
Interventions: repository corticotropin injection; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Keratoconjunctivitis Sicca, Xeropthalmia
Interventions: Acupuncture, Sham acupuncture; Procedure
Lead sponsor: Walter Reed Army Medical Center; Federal
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Healthy, Sicca Syndrome, Sjögren's Syndrome
Interventions: Biopsy; Procedure
Lead sponsor: Biogen; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 4
States / cities: Hartford, Connecticut • Boston, Massachusetts • Philadelphia, Pennsylvania + 1 more

Conditions: Dry Eye, Kerato Conjunctivitis Sicca
Interventions: Tyrvaya Nasal Pump; Drug
Lead sponsor: Oyster Point Pharma, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Newport Beach, California

Conditions: Dry Eye Disease, Keratoconjunctivitis Sicca
Interventions: Lotemax, Restasis; Drug
Lead sponsor: Ophthalmic Consultants of Long Island; Other
Eligibility: 30 Years to 80 Years
Enrollment: 5 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Lynbrook, New York

Conditions: Keratoconjunctivitis Sicca
Interventions: Pimecrolimus, Vehicle; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Enrollment: 440 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Keratoconjunctivitis Sicca
Interventions: Systane Ocular Drops (OTC), Placebo - Saline Drops; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 88 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Ectropion
Interventions: Hyaluronic acid, Saline; Procedure
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 21 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Sjögren Syndrome
Interventions: CFZ533, Placebo; Drug · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 273 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 8
States / cities: Suwanee, Georgia • Indianapolis, Indiana • Baton Rouge, Louisiana + 5 more

Conditions: Chronic Graft-versus-host Disease
Interventions: R348 Ophthalmic Solution, 0.2%, R348 Ophthalmic Solution, 0.5%, Placebo Ophthalmic Solution; Drug · Other
Lead sponsor: Rigel Pharmaceuticals; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 2
States / cities: Plantation, Florida • Boston, Massachusetts

Conditions: Keratoconjunctivitis Sicca
Interventions: 1% Tavilermide Ophthalmic Solution, Placebo Ophthalmic Solution; Drug
Lead sponsor: Mimetogen Pharmaceuticals USA, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Torrance, California

Conditions: Keratoconjunctivitis Sicca, Dry Eye Disease
Interventions: OTX-101 0.05%, OTX-101 0.09%, Vehicle; Drug
Lead sponsor: Sun Pharmaceutical Industries Limited; Industry
Eligibility: 18 Years and older
Enrollment: 455 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Sjogren's Syndrome, Oral Health
Interventions: Not listed
Lead sponsor: National Institute of Dental and Craniofacial Research (NIDCR); NIH
Eligibility: 18 Years and older
Enrollment: 166 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Dry Eye Syndrome, Keratoconjunctivitis Sicca
Interventions: 0.05% Voclosporin Ophthalmic Solution (VOS), 0.10% VOS, 0.20% VOS, Vehicle Ophthalmic Solution; Drug
Lead sponsor: Aurinia Pharmaceuticals Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 508 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 9
States / cities: Newport Beach, California • Colorado Springs, Colorado • Louisville, Kentucky + 6 more

Conditions: Dry Eye Disease
Interventions: INV-102, Vehicle; Drug
Lead sponsor: Invirsa, Inc.; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Rush, New York

Conditions: Keratoconjunctivitis Sicca
Interventions: Omega-3 Fatty Acid, Soybean Soft Gels; Dietary Supplement
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Kerato Conjunctivitis Sicca
Interventions: KPI-121 Ophthalmic Suspension, Vehicle; Drug
Lead sponsor: Kala Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 901 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 81
States / cities: Birmingham, Alabama • Dothan, Alabama • Chandler, Arizona + 64 more

Conditions: Keratoconjunctivitis Sicca
Interventions: PRK with conjunctival impression cytology before and after surgery, LASIK with conjunctival impression cytology before and after surgery; Procedure
Lead sponsor: Walter Reed National Military Medical Center; Federal
Eligibility: 21 Years to 40 Years
Enrollment: 146 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2016
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Dry Eye Disease
Interventions: CequaTM (Cyclosporine 0.09%) ophthalmic solution; Drug
Lead sponsor: Sun Pharmaceutical Industries Limited; Industry
Eligibility: 18 Years and older
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 5
States / cities: Fort Myers, Florida • Jacksonville, Florida • Panama City, Florida + 2 more

Conditions: Keratoconjunctivitis Sicca
Interventions: Not listed
Lead sponsor: ORA, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 1
States / cities: Andover, Massachusetts

Conditions: Keratoconjunctivitis Sicca
Interventions: glycerin, polyethylene glycol 400/propylene glycol; Drug
Lead sponsor: Calm Water Therapeutics LLC; Industry
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Keratoconjunctivitis Sicca
Interventions: Rebamipide 1%, Rebamipide 2%, Placebo; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 762 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 60
States / cities: Birmingham, Alabama • Flagstaff, Arizona • Little Rock, Arkansas + 47 more

Search by objective public record fields.

Levocarnitine for Dry Eye in Sjogren's Syndrome

A Study to Assess the Safety and Efficacy of ECF843 vs Vehicle in Subjects With Dry Eye Disease

Repository Corticotropin Injection in Keratoconjunctivitis Sicca

Acupuncture Treatment of Dry Eye

A Longitudinal, Observational Biomarker Study in Participants With Primary Sjogren's Syndrome

A Study Evaluating the Safety of the Nasal Pump

Multicenter, Randomized, Controlled Study of the Effect of Lotemax on Initiation of Dry Eye Treatment With Restasis

Safety and Efficacy of Pimecrolimus Ophthalmic Suspension in Patients With Moderate to Severe Keratoconjunctivitis Sicca

Effects of Systane Versus Saline in Maintaining Tear Film Stability at Determined Time Points

Hyaluronic Acid Gels for Lower Lid Retraction

Study of Safety and Efficacy of Multiple Doses of CFZ533 in Two Distinct Populations of Patients With Sjogren's Syndrome

Safety and Efficacy Study of R932348 Ophthalmic Solution in Chronic Ocular Graft Versus Host Disease Patients(DROPS-2)

A Safety and Efficacy Study of Tavilermide (MIM-D3) Ophthalmic Solution for the Treatment of Dry Eye Disease

Phase 2/3 Dose-Ranging Study of the Safety and Efficacy of OTX-101 in the Treatment of Keratoconjunctivitis Sicca

Oral Health Needs Assessment of Sjogren s Syndrome and Salivary Gland Dysfunction Cohorts and Healthy Volunteers Evaluating Oral Health Disparities as Determinants of Oral Health in a High-Risk Population

Dose Ranging Study to Assess the Efficacy and Safety of Voclosporin Ophthalmic Solution in Subjects With Dry Eye Syndrome

Study of INV-102 Ophthalmic Solution in Adults With Moderate to Severe Dry Eye Disease

Omega-3 Fatty Acid Supplements and Dry Eye

Safety and Efficacy of KPI-121 in Subjects With DED

Goblet Cell Response and Dry Eye Symptoms After PRK and LASIK

Effect of Cequa™ in Subjects With Dry Eye Disease

Effect of Controlled Adverse Environment (CAE) on Tear Film Stability

Tear Film Break-up Time After Instillation of Artificial Tears

Study of Rebamipide Eye Drops to Treat Dry Eye